Skip to main content

Tweets

FDA has approved secukinumab (Cosentyx) 150 mg for the treatment of adult patients with polymyalgia PMR w/ an inadequate response to steroids or who cannot tolerate steroid taper.https://t.co/WrlLYrLRds

Dr. John Cush @RheumNow ( View Tweet )

13 minutes 34 seconds ago
FDA has approved secukinumab (Cosentyx) 150 mg for the treatment of adult patients with polymyalgia PMR w/ an inadequate response to steroids or who cannot tolerate steroid taper.https://t.co/xkdUobmNTA

Dr. John Cush @RheumNow ( View Tweet )

14 minutes 6 seconds ago
FDA has approved secukinumab (Cosentyx) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.https://t.co/vaUYXwglVB

Dr. John Cush @RheumNow ( View Tweet )

15 minutes 12 seconds ago
Not All Pain in Rheumatic Disease is Inflammatory In a session at the Global Rheumatology Summit, Dr. Daniel Clauw, an expert on the topic, explained that fibromyalgia can occur in isolation in a “top-down” fashion, or can be secondary to inflammatory autoimmune diseases in a https://t.co/AMUm52SKsB
Dr. John Cush @RheumNow ( View Tweet )
1 hour 9 minutes ago
Missed #ACR26? Or just trying to catch up? Dr. Jack Cush shares why he returns to ACR Convergence every year—and how to make the most of this year's research with RheumNow recaps, expert analysis, podcasts & RheumIQ. Catch up: https://t.co/1bELsAsOXw https://t.co/ZQRt4GUUPM
Dr. John Cush @RheumNow ( View Tweet )
1 hour 39 minutes ago
Points to Consider in D2M/Treatment Refractory axSpA New ASAS guidance presented at #ACR26 outlines 10 points to consider, from diagnostic reassessment to inflammation, mimics & treatment adherence. Dr. Sheila Reyes breaks it down: https://t.co/vvT2qWbbM7 https://t.co/Crf5uisIvS
Dr. John Cush @RheumNow ( View Tweet )
3 hours 7 minutes ago
To Pulse or Not to Pulse in ANCA Associated Vasculitis? New #ACR26 data found no significant remission benefit with pulse steroids, but serious infections were higher (31% vs 14%). Is it time to rethink their use? Dr. Michael Putman weighs in: https://t.co/b6cJkI2aXc https://t.co/rM3eoRBJYW
Dr. John Cush @RheumNow ( View Tweet )
14 hours 9 minutes ago
What does CAR-T safety look like between autoimmune disease and heme-onc? Here's CRS and ICANS within the cohorts so far (although don't forget about the lymphodepletion) Anca Askanase @HSpecialSurgery #ACR26 @RheumNow https://t.co/GkDGDiOET4
David Liew @drdavidliew ( View Tweet )
15 hours 3 minutes ago
Two Prescriptions, One Patient Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
Dr. John Cush @RheumNow ( View Tweet )
15 hours 9 minutes ago
ACR 2026 Day 4 Report The last day of ACR 2026 was a half-day but a busy day, with several exciting reports, especially coming from the late-breaking abstracts. https://t.co/wBfrQhwZHy https://t.co/plZgG0Y7VN
Dr. John Cush @RheumNow ( View Tweet )
16 hours 9 minutes ago
ACR 2026: RA Topic Panel https://t.co/4Jttct8XKe

Dr. John Cush @RheumNow ( View Tweet )

16 hours 9 minutes ago
TRBV9+ a novel treatment approach for AxSpA? https://t.co/sNV9KsgvNa https://t.co/b6fRnwdLYf
Dr. John Cush @RheumNow ( View Tweet )
16 hours 39 minutes ago
Check the genetics in your patients with ILD A common misconception is that genetic variants don’t cause disease in adults, says Dr. Korf. According to Dr. Bogunovic, 1 in 4 adults will have a first manifestation of genetic error of immunity in adulthood. Genetics seems to be https://t.co/qRUV0oiu0a
Dr. John Cush @RheumNow ( View Tweet )
18 hours 9 minutes ago
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/PHm1fF3Tg4
Dr. John Cush @RheumNow ( View Tweet )
18 hours 54 minutes ago
Cardiovascular Risk in Axial Spondyloarthritis When a patient with axial spondyloarthritis patient sits in your clinic, their joint inflammation is only half the story. To truly achieve disease control, one should ask: “Am I consistently and aggressively screening them all for https://t.co/t0hLcKIowz
Dr. John Cush @RheumNow ( View Tweet )
20 hours 9 minutes ago
×